Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.
Source: xStation
Daily Summary: Nvidia drives the Nasdaq 100 up 1.3% (27.08.2026)
US Open: Nvidia breaks the curse โ 7% gain drives the Nasdaq! (27.08.2026)
Stock of the week: NVIDIA: The Best Company in the World?
Semiconductor stocks show a muted reaction to Nvidiaโs report